🇬🇷 Medical cannabis in Greece

C — product- and indication-gated. Cannabis is lawful only as 'τελικά προϊόντα φαρμακευτικής κάνναβης' (final pharmaceutical cannabis products) holding an EOF 'ειδική έγκριση κυκλοφορίας' (special marketing approval), prescribable only when approved medicines have failed, in indications fixed by the EOF core SPC, and sold through pharmacies at state-set maximum prices without reimbursement.

Legal basis per the ΕΟΦ (Εθνικός Οργανισμός Φαρμάκων, National Organisation for Medicines): Ν. 4139/2013 (ΦΕΚ Α' 74) 'Νόμος περί εξαρτησιογόνων ουσιών' as amended by Ν. 4523/2018 (which created the medical-cannabis category) and Ν. 4801/2021 (ΦΕΚ Α' 83); implementing joint ministerial decisions ΚΥΑ Δ3(γ) 40642/6-8-2024 (ΦΕΚ Β' 4581) 'Όροι και προϋποθέσεις για την παραγωγή, κυκλοφορία και εξαγωγή τελικών προϊόντων φαρμακευτικής κάνναβης', ΚΥΑ 27462/2022 (ΦΕΚ Β' 1151) on cultivation/processing and 97673/2023 (ΦΕΚ Β' 6227). Licensed activities cover Cannabis sativa L. varieties above 0.2% THC; distribution channels named by EOF are pharmacies, pharmaceutical wholesalers, treatment facilities, private clinics and public hospitals under EOF oversight. Pricing is governed by Υ.Α. Δ3(α)/Γ.Π. 72349/03-01-2023 (ΦΕΚ Β' 5) as amended by Δ3(α) 19962/13-5-2026 (ΦΕΚ Β' 2716).

Source: ΕΟΦ — Σχετικά με την Φαρμακευτική Κάνναβη (EOF: About pharmaceutical cannabis, PDF, 2025) · read 27 September 2026

EOF-approved final products only: as of September 2026 the Ministry of Health price bulletins list 24 items from Tikun Olam Greece (dried flowers in THC-dominant, balanced and CBD-dominant strains, 5 g and 10 g; oil solutions 3% and 9% THC, 10 g vials) plus two dried-flower products from Curity Pharma (Dravexol 30% THC, Equilo 9% THC/10% CBD) added on 16 September 2026. Sativex and Epidyolex are separate authorised medicines.

Price bulletin Δ3(α) 22541/20-5-2026: 24 SKUs, all 'ΤΙΚΟΥΝ ΟΛΑΜ … ΑΝΩΝΥΜΗ ΕΤΑΙΡΕΙΑ' — e.g. GRAPERA/CAPJERA DR.FL.CAN 30–31% THC, NOGARON 27%, OZIA 22%, EREZ/EREVRON 19%, MIDNIGHT/MAROXIM 9% THC/13% CBD, AVIDEKEL/DAVIKEL ≤1% THC/18.5% CBD, and EREZ ORO/EREVRON ORO oils 3% and 9% THC w/w. Bulletin Δ3(α) 37775/16-9-2026 adds DRAVEXOL (THC 30%, CBD ≤1%) and EQUILO (THC 9%, CBD 10%) dried flowers, 5 g and 10 g, from Curity Pharma A.E. The EOF core SPC (16th session, 25 Nov 2025) covers routes by inhalation, nasal, oral, oromucosal, buccal, sublingual and rectal.

Source: Υπουργείο Υγείας — Επικαιροποίηση Δελτίου Τιμών Τελικών Προϊόντων Φαρμακευτικής Κάνναβης, Υ.Α. Δ3(α) 22541/20-5-2026 (Ministry of Health price bulletin, product table PDF) · read 27 September 2026

The EOF core SPC restricts prescribing to adults and to cases where approved medicines proved unfeasible, intolerable or ineffective; whether prescribing is limited to particular specialties is not stated in any official page opened.

Core SPC (ΕΟΦ, ΚΥΑ Δ3(γ)40642/2024): 'Η συνταγογράφηση … δεν μπορεί σε καμία περίπτωση να αποτελεί θεραπεία πρώτης επιλογής' (prescribing can never be first-line) and may be considered only where 'η χρήση ήδη εγκεκριμένων … φαρμάκων αποδείχθηκε μη-εφικτή, ή/και μη-ανεκτή ή/και μη-αποτελεσματική'. Indications (adults): severe nausea/vomiting from chemotherapy, radiotherapy or HIV/HCV therapy; chronic pain linked to cancer or CNS/peripheral nerve disorders (neuropathic, phantom limb, trigeminal and post-herpetic neuralgia); spasticity in MS or spinal cord injury; appetite stimulation in palliative care for cancer or AIDS; symptomatic relief in inflammatory bowel disease. 'Αντενδείκνυται σε παιδιά και εφήβους' (contraindicated in children and adolescents). The full text of ΚΥΑ 40642/2024 and Ν. 4801/2021, which may set specialty or prescription-form rules, could not be opened (et.gr redirect loop).

Source: ΕΟΦ — Πυρήνας Περίληψης Χαρακτηριστικών Τελικών Προϊόντων Φαρμακευτικής Κάνναβης (Core SPC, 16η συνεδρίαση 25-11-2025) · read 27 September 2026

Not verified from primary text in this session. Final cannabis products above 0.2% THC fall under the narcotics law (Ν. 4139/2013), so a controlled-substance prescription regime applies; the exact form (special narcotic prescription, e-prescription, quantity or day limits) is set in Ν. 4801/2021 and ΚΥΑ 40642/2024, which could not be opened.

EOF names Ν. 4139/2013, Ν. 4523/2018, Ν. 4801/2021 and ΚΥΑ Δ3(γ) 40642/2024 (ΦΕΚ Β' 4581) as the governing texts. The price bulletins confirm pharmacy retail sale with 6% VAT and maximum retail prices 'σε όλη την επικράτεια'. Attempts to download ΦΕΚ Α' 83/2021 and ΦΕΚ Β' 4581/2024 from et.gr failed ('too many redirects'), so validity period, quantity limits and e-prescription handling are left unknown rather than guessed.

Source: ΕΟΦ — Φαρμακευτική κάνναβη (EOF pharmaceutical cannabis page listing the governing laws and ΚΥΑ) · read 27 September 2026

Not published. No EOF or Ministry of Health page addresses whether a final cannabis product may be first prescribed in a video consultation.

The EOF core SPC and the price bulletins are silent on consultation format. Because the product is a narcotic under Ν. 4139/2013 and last-line only, a documented treatment history is implied, but no official rule on remote prescribing was found.

Source: ΕΟΦ — Πυρήνας Περίληψης Χαρακτηριστικών (Core SPC, 25-11-2025) · read 27 September 2026

Community pharmacies sell the products at or below the state maximum retail price; EOF also lists wholesalers, clinics and public hospitals as lawful distribution points. No official mail-order channel is described.

EOF: distribution 'φαρμακεία, φαρμακαποθήκες, θεραπευτήρια, ιδιωτικές κλινικές, δημόσια νοσοκομεία' under EOF supervision. Ministry of Health Υ.Α. Δ3(α) 37775/16-9-2026, Article 1: the annexed table sets 'ανώτατες λιανικές τιμές' for the whole territory; Article 2: wholesale and hospital prices exclude VAT, retail includes it. No register marks which pharmacies stock cannabis.

Source: Υπουργείο Υγείας — Υ.Α. Δ3(α) 37775/16-9-2026 «Δελτίο Τιμών Νέων Τελικών Προϊόντων Φαρμακευτικής Κάνναβης» (decision PDF) · read 27 September 2026

None. All final cannabis products are classified as not reimbursed by ΕΟΠΥΥ (the national health insurer); patients pay the full retail price.

Every line of the 20 May 2026 price table carries 'Μη Αποζημιούμενο' (not reimbursed), and the decision's financial-impact note states the products are 'μη αποζημιούμενα' by ΕΟΠΥΥ so price changes carry no budget cost. The 16 September 2026 table for Dravexol/Equilo repeats the non-reimbursed status.

Source: Υπουργείο Υγείας — Υ.Α. Δ3(α) 22541/20-5-2026 (price bulletin decision PDF) · read 27 September 2026

Official maximum retail prices (incl. 6% VAT): dried flowers €51.39–64.25 per 5 g and €94.56–128.48 per 10 g depending on strain; oil solutions €37.27 (3% THC) and €75.81 (9% THC) per 10 g vial.

From the Ministry of Health tables: GRAPERA/CAPJERA (30–31% THC) €59.42/5 g, €104.59/10 g; NOGARON (27%) €57.81/€101.76; OZIA, EREZ, EREVRON (19–22%) €57.18/€100.63; MIDNIGHT, MAROXIM (9% THC/13% CBD) €51.39/€94.56; AVIDEKEL, DAVIKEL (CBD 18.5%) €64.25/€128.48; EREZ ORO/EREVRON ORO oils 9% €75.81, 3% €37.27 per 10 g. New in Sept 2026: DRAVEXOL €59.42/5 g, €104.59/10 g; EQUILO €51.39/5 g, €94.56/10 g. Ex-factory and wholesale prices are also published (e.g. GRAPERA 5 g €46.25 / €48.75).

Source: Υπουργείο Υγείας — Πίνακας Νέων Τελικών Προϊόντων Φαρμ. Κάνναβης Dravexol/Equilo (price table PDF, 16-9-2026) · read 27 September 2026

The EOF core SPC forbids driving and operating machinery for at least seven days after the dose is stabilised and for as long as CNS side-effects persist, and excludes professional drivers from treatment. The road-traffic statute on drug driving could not be opened in this session.

Core SPC section 4.7: 'Απαγορεύεται η οδήγηση και ο χειρισμός μηχανημάτων για τουλάχιστον επτά ημέρες μετά τη σταθεροποίηση της δοσολογίας' and while adverse CNS effects last; professional drivers are not eligible. Greece's Κώδικας Οδικής Κυκλοφορίας (Highway Code) penalises driving under the influence of narcotic substances; whether any THC threshold or medical defence exists could not be verified because the statute text was not reachable (see notes).

Source: ΕΟΦ — Πυρήνας Περίληψης Χαρακτηριστικών Τελικών Προϊόντων Φαρμακευτικής Κάνναβης, §4.7 (Core SPC, 25-11-2025) · read 27 September 2026

Greece is in Schengen, so a resident travelling with a narcotic medicine needs the Schengen Article 75 certificate from the competent Greek authority; which Greek authority issues it and what applies to non-EU visitors bringing cannabis products in is not published on any EOF or Ministry page opened.

The EOF site has no 'travelling with medicines' section (checked the homepage navigation and the cannabis page). Final cannabis products are narcotics under Ν. 4139/2013, so the Schengen Implementing Convention Art. 75 regime (certificate, max 30 days) applies in principle to Greek residents, but the issuing authority, form and any national import rule for third-country travellers were not found. Treat as not published.

Source: ΕΟΦ — Φαρμακευτική κάνναβη (EOF cannabis page; no traveller guidance present) · read 27 September 2026

No official text bars a visitor from being prescribed a final cannabis product by a Greek doctor if the last-line criteria are met, but whether a foreign or foreign-telemedicine prescription can be filled, and how a visitor may bring their own supply in, is not published by EOF or the Ministry of Health.

(1) Non-resident prescription: the EOF core SPC sets clinical, not residency, conditions; the practical gate is documentation of failed prior therapy and the (unverified) narcotic-prescription form — not published. (2) Foreign EU prescription: Greece's transposition of Directive 2011/24/EU Art. 11 (Ν. 4213/2013) could not be opened; whether narcotic prescriptions are excluded under Art. 11(6) is therefore not verified — not published here. (3) Bringing medicine in: Schengen residents rely on the Art. 75 certificate from their home country; no Greek customs/health page on personal import of cannabis products was found — not published. (4) Foreign telemedicine prescription: not published; depends on (2).

Source: ΕΟΦ — Πυρήνας Περίληψης Χαρακτηριστικών (Core SPC, 25-11-2025) · read 27 September 2026

The market is growing rather than the rules changing: a second producer (Curity Pharma) entered the official price list on 16 September 2026, and prices of existing products were cut on 20 May 2026 after a pricing-rule amendment; objections to the new bulletin were open until 23 September 2026.

Υ.Α. Δ3(α) 19962/13-5-2026 (ΦΕΚ Β' 2716) amended the 2023 cannabis pricing decision, followed by bulletin Δ3(α) 22541/20-5-2026 incorporating producer price-reduction requests; Υ.Α. Δ3(α) 37775/16-9-2026 lists Dravexol and Equilo, with objections to deltiatimwn_enstaseis@eof.gr by 23 September 2026, 23:59. EOF updated the core SPC at its 16th session on 25 November 2025. No pending change to prescribing or reimbursement rules is announced on the pages opened.

Source: Υπουργείο Υγείας — Δελτία Τιμών (Ministry of Health price bulletins list) · read 27 September 2026

No official count of patients or prescriptions is published by EOF, the Ministry of Health or ΕΟΠΥΥ; because products are not reimbursed, no insurer statistics exist.

Neither the EOF cannabis page nor the price-bulletin decisions report volumes. The only market-size indicator published officially is the number of listed products (26 SKUs from two producers as of September 2026).

Source: ΕΟΦ — Φαρμακευτική κάνναβη · read 27 September 2026